VISION — Study of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer

Phase 3 · 2021 · Prostate Cancer

Design

Randomized trial of 177Lu-PSMA-617 plus standard of care vs. standard of care alone in PSMA-positive mCRPC.

Population

PSMA-PET-positive metastatic castration-resistant prostate cancer after >=1 taxane and >=1 novel androgen-axis agent.

Primary Endpoint

radiographic progression-free survival (rPFS) and overall survival (OS)

Key Result

Median OS 15.3 vs 11.3 mo (HR 0.62); median rPFS 8.7 vs 3.4 mo (HR 0.40).

Guideline Impact

NCCN category 1 for PSMA-positive mCRPC after novel hormonal therapy and taxane